Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.33
HZNP's Cash-to-Debt is ranked lower than
77% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. HZNP: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
HZNP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.72 Max: 2.56
Current: 0.33
0.07
2.56
Equity-to-Asset 0.24
HZNP's Equity-to-Asset is ranked lower than
91% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. HZNP: 0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
HZNP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.44 Max: 0.7
Current: 0.24
-0.77
0.7
Debt-to-Equity 1.90
HZNP's Debt-to-Equity is ranked lower than
94% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. HZNP: 1.90 )
Ranked among companies with meaningful Debt-to-Equity only.
HZNP' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.51  Med: 0.64 Max: 1.9
Current: 1.9
-2.51
1.9
Debt-to-EBITDA -11.41
HZNP's Debt-to-EBITDA is ranked lower than
99.99% of the 511 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. HZNP: -11.41 )
Ranked among companies with meaningful Debt-to-EBITDA only.
HZNP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.41  Med: -0.43 Max: 24.21
Current: -11.41
-11.41
24.21
Piotroski F-Score: 3
Altman Z-Score: 0.07
Beneish M-Score: -3.16
WACC vs ROIC
4.56%
-16.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -40.91
HZNP's Operating Margin % is ranked lower than
82% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.71 vs. HZNP: -40.91 )
Ranked among companies with meaningful Operating Margin % only.
HZNP' s Operating Margin % Range Over the Past 10 Years
Min: -1841.5  Med: -57.9 Max: 7.31
Current: -40.91
-1841.5
7.31
Net Margin % -45.28
HZNP's Net Margin % is ranked lower than
83% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. HZNP: -45.28 )
Ranked among companies with meaningful Net Margin % only.
HZNP' s Net Margin % Range Over the Past 10 Years
Min: -1635.12  Med: -201.31 Max: 5.22
Current: -45.28
-1635.12
5.22
ROE % -42.20
HZNP's ROE % is ranked lower than
83% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. HZNP: -42.20 )
Ranked among companies with meaningful ROE % only.
HZNP' s ROE % Range Over the Past 10 Years
Min: -523.78  Med: -107.35 Max: 4.27
Current: -42.2
-523.78
4.27
ROA % -12.15
HZNP's ROA % is ranked lower than
76% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. HZNP: -12.15 )
Ranked among companies with meaningful ROA % only.
HZNP' s ROA % Range Over the Past 10 Years
Min: -186.55  Med: -59.51 Max: 1.89
Current: -12.15
-186.55
1.89
ROC (Joel Greenblatt) % -1877.66
HZNP's ROC (Joel Greenblatt) % is ranked lower than
93% of the 850 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.46 vs. HZNP: -1877.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HZNP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7948.82  Med: -2263.21 Max: 520.88
Current: -1877.66
-7948.82
520.88
3-Year Revenue Growth Rate 73.80
HZNP's 3-Year Revenue Growth Rate is ranked higher than
97% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. HZNP: 73.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HZNP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 115.5
Current: 73.8
0
115.5
3-Year EPS without NRI Growth Rate -23.70
HZNP's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. HZNP: -23.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HZNP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -52 Max: -23.7
Current: -23.7
GuruFocus has detected 3 Warning Signs with Horizon Pharma PLC HZNP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HZNP's 30-Y Financials

Financials (Next Earnings Date: 2018-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

HZNP Guru Trades in Q1 2017

Ken Heebner Sold Out
Julian Robertson Sold Out
Steven Cohen 427,200 sh (-25.43%)
Joel Greenblatt 37,797 sh (-70.11%)
Paul Tudor Jones 20,100 sh (-80.69%)
» More
Q2 2017

HZNP Guru Trades in Q2 2017

Jim Simons 107,900 sh (New)
John Paulson 4,935,500 sh (New)
Steven Cohen 3,653,500 sh (+755.22%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
» More
Q3 2017

HZNP Guru Trades in Q3 2017

Paul Tudor Jones 25,688 sh (New)
Jim Simons 1,109,400 sh (+928.17%)
John Paulson 5,578,850 sh (+13.04%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 2,809,500 sh (-23.10%)
» More
Q4 2017

HZNP Guru Trades in Q4 2017

Paul Tudor Jones 96,558 sh (+275.89%)
Jim Simons 2,279,400 sh (+105.46%)
John Paulson 7,870,700 sh (+41.08%)
Steven Cohen 372,800 sh (-86.73%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-12-31 Add 41.08%0.65%$13 - $15.07 $ 14.100%7,870,700
John Paulson 2017-09-30 Add 13.04%0.15%$11.54 - $14.05 $ 14.1011%5,578,850
John Paulson 2017-06-30 New Buy0.8%$9.65 - $15.75 $ 14.1013%4,935,500
Joel Greenblatt 2017-06-30 Sold Out 0.01%$9.65 - $15.75 $ 14.1013%0
Joel Greenblatt 2017-03-31 Reduce -70.11%0.02%$14.37 - $18.09 $ 14.10-13%37,797
Ken Heebner 2017-03-31 Sold Out 1.1%$14.37 - $18.09 $ 14.10-13%0
Julian Robertson 2017-03-31 Sold Out 2.33%$14.37 - $18.09 $ 14.10-13%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSX:APH, TSE:4540, NAS:MDCO, NAS:OPK, NAS:IRWD, XTER:EVT, SZSE:000078, SZSE:300110, BOM:532296, HKSE:02005, SHSE:600277, SHSE:600216, XKRX:145020, XLJU:KRKG, SZSE:300601, NAS:SUPN, SZSE:002390, TSE:4521, SZSE:300199, TSE:4527 » details
Traded in other countries:HPR.Germany,
Headquarter Location:Ireland
Horizon Pharma PLC is a pharmaceutical company. The company focuses on identifying, developing, and commercializing of differentiated and accessible medicines to address unmet medical needs mainly in the US.

Horizon Pharma is a specialty and generic drug manufacturing company. The company is focused on the identification, development, acquisition, and commercialization of differentiated and accessible medicines that address unmet medical needs. The overwhelming majority of revenue is generated in the United States. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Horizon Pharma PLC

Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis Community
Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial Results and Host Webcast on Feb. 28, 2018
Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune
Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments
Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic Cystinosis

Ratios

vs
industry
vs
history
Forward PE Ratio 11.24
HZNP's Forward PE Ratio is ranked higher than
77% of the 73 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.67 vs. HZNP: 11.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.36
HZNP's PB Ratio is ranked higher than
61% of the 825 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. HZNP: 2.36 )
Ranked among companies with meaningful PB Ratio only.
HZNP' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2.23 Max: 14.94
Current: 2.36
0.8
14.94
PS Ratio 2.11
HZNP's PS Ratio is ranked higher than
63% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. HZNP: 2.11 )
Ranked among companies with meaningful PS Ratio only.
HZNP' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.97 Max: 19
Current: 2.11
1.47
19
Price-to-Free-Cash-Flow 8.43
HZNP's Price-to-Free-Cash-Flow is ranked higher than
88% of the 217 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.63 vs. HZNP: 8.43 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HZNP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 8.92 Max: 433
Current: 8.43
5.02
433
Price-to-Operating-Cash-Flow 8.28
HZNP's Price-to-Operating-Cash-Flow is ranked higher than
85% of the 294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.74 vs. HZNP: 8.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HZNP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.9  Med: 8.58 Max: 209.52
Current: 8.28
4.9
209.52
EV-to-EBIT -8.01
HZNP's EV-to-EBIT is ranked lower than
99.99% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.21 vs. HZNP: -8.01 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -2.4 Max: 219.8
Current: -8.01
-775.4
219.8
EV-to-EBITDA -21.54
HZNP's EV-to-EBITDA is ranked lower than
99.99% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. HZNP: -21.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.6 Max: 518
Current: -21.54
-608
518
EV-to-Revenue 3.33
HZNP's EV-to-Revenue is ranked higher than
50% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. HZNP: 3.33 )
Ranked among companies with meaningful EV-to-Revenue only.
HZNP' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 4.9 Max: 30.2
Current: 3.33
0.5
30.2
Current Ratio 1.64
HZNP's Current Ratio is ranked lower than
68% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. HZNP: 1.64 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.89 Max: 4.39
Current: 1.64
0.16
4.39
Quick Ratio 1.52
HZNP's Quick Ratio is ranked lower than
59% of the 812 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.88 vs. HZNP: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.57 Max: 4.27
Current: 1.52
0.16
4.27
Days Inventory 88.96
HZNP's Days Inventory is ranked higher than
67% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.37 vs. HZNP: 88.96 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 59.25 Max: 184.95
Current: 88.96
13.1
184.95
Days Sales Outstanding 130.54
HZNP's Days Sales Outstanding is ranked lower than
79% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.67 vs. HZNP: 130.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08  Med: 90.85 Max: 130.54
Current: 130.54
67.08
130.54
Days Payable 22.00
HZNP's Days Payable is ranked lower than
89% of the 630 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.56 vs. HZNP: 22.00 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 22  Med: 183.99 Max: 410.36
Current: 22
22
410.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.70
HZNP's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.00 vs. HZNP: -34.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HZNP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -428.1  Med: -61.1 Max: 0
Current: -34.7
-428.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.07
HZNP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. HZNP: 1.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HZNP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.95  Med: 2.3 Max: 29.51
Current: 1.07
0.95
29.51
Price-to-Median-PS-Value 0.53
HZNP's Price-to-Median-PS-Value is ranked higher than
88% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.05 vs. HZNP: 0.53 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HZNP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.44  Med: 1.04 Max: 4.27
Current: 0.53
0.44
4.27
Earnings Yield (Greenblatt) % -12.50
HZNP's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 868 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.18 vs. HZNP: -12.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HZNP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1744.4  Med: -6.3 Max: 2.6
Current: -12.5
-1744.4
2.6

More Statistics

Revenue (TTM) (Mil) $1,092.36
EPS (TTM) $ -3.05
Beta1.02
Short Percentage of Float6.62%
52-Week Range $9.45 - 17.69
Shares Outstanding (Mil)163.89

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,054 1,148 1,224
EBIT (Mil $) 383 413 469
EBITDA (Mil $) 389 420 478
EPS ($) 1.09 1.26 1.55
EPS without NRI ($) 1.09 1.26 1.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}